PMID- 32154748
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20210802
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 16
IP  - 4
DP  - 2020 Apr
TI  - Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality 
      assessment and potential prevention strategies.
PG  - 373-387
LID - 10.1080/1744666X.2020.1740591 [doi]
AB  - Introduction: The clinical manifestations of cutaneous adverse drug reactions are 
      variable with different severity. Stevens-Johnson syndrome (SJS) and toxic 
      epidermal necrolysis (TEN) are life-threatening severe cutaneous adverse 
      reactions (SCARs) majorly caused by drugs and mediated by cytotoxic T cells.Areas 
      covered: In this review, we focus on risk factors that contribute to the 
      development of SJS/TEN and review the updated immune mechanism, preventive 
      strategies as well as current therapeutic approaches for SJS/TEN.Expert opinion: 
      The progress of SJS/TEN researches reveals that cytotoxic T cells majorly 
      activated by drug interacted with the human leukocyte antigen (HLA) and T cell 
      receptors play an important role for the immune mechanism of SJS/TEN. 
      Several clinical assessment tools and in vitro drug-T cells activation tests have 
      been developed to identify the causality of SJS/TEN. New therapeutic approaches 
      and biologics such as TNF-alpha antagonist have been conducted to improve 
      the prognosis of SJS/TEN.
FAU - Lin, Chu-Chi
AU  - Lin CC
AUID- ORCID: 0000-0001-9017-5004
AD  - Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, 
      Chang Gung Memorial Hospital, Linkou, Taipei, Keelung, Taiwan.
AD  - Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial 
      Hospital, Taoyuan, Taiwan.
FAU - Chen, Chun-Bing
AU  - Chen CB
AUID- ORCID: 0000-0002-7378-4235
AD  - Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, 
      Chang Gung Memorial Hospital, Linkou, Taipei, Keelung, Taiwan.
AD  - Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial 
      Hospital, Taoyuan, Taiwan.
AD  - Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
AD  - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung 
      University, Kwei-Shan, Taoyuan, Taiwan.
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
AD  - Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China.
AD  - Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial 
      Hospital, Keelung, Taiwan.
FAU - Wang, Chuang-Wei
AU  - Wang CW
AD  - Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, 
      Chang Gung Memorial Hospital, Linkou, Taipei, Keelung, Taiwan.
AD  - Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial 
      Hospital, Taoyuan, Taiwan.
FAU - Hung, Shuen-Iu
AU  - Hung SI
AUID- ORCID: 0000-0001-6531-5538
AD  - Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial 
      Hospital, Taoyuan, Taiwan.
FAU - Chung, Wen-Hung
AU  - Chung WH
AUID- ORCID: 0000-0003-1681-0959
AD  - Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, 
      Chang Gung Memorial Hospital, Linkou, Taipei, Keelung, Taiwan.
AD  - Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial 
      Hospital, Taoyuan, Taiwan.
AD  - Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
AD  - Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China.
AD  - Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial 
      Hospital, Keelung, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200402
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Biological Products)
RN  - 0 (HLA Antigens)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Anti-Allergic Agents/therapeutic use
MH  - Biological Products/therapeutic use
MH  - HLA Antigens/immunology
MH  - Humans
MH  - Risk Factors
MH  - Skin/*pathology
MH  - Stevens-Johnson Syndrome/drug therapy/epidemiology/*immunology
MH  - T-Lymphocytes/*immunology
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
OTO - NOTNLM
OT  - Human leukocyte antigen (HLA)
OT  - Stevens-Johnson syndrome (SJS)
OT  - T cell receptors
OT  - severe cutaneous adverse reactions
OT  - toxic epidermal necrolysis (TEN)
EDAT- 2020/03/11 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/03/11 06:00
PHST- 2020/03/11 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
PHST- 2020/03/11 06:00 [entrez]
AID - 10.1080/1744666X.2020.1740591 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2020 Apr;16(4):373-387. doi: 
      10.1080/1744666X.2020.1740591. Epub 2020 Apr 2.